CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01413516
NCT01413516Phase 2Completed
CompareCT.gov

A Two-Part Pilot Study of Dosing, Safety and Efficacy of Varenicline Initiated During an Acute Smoke-free Hospitalization and Continued Post-Hospitalization

Stanford University·interventional·Posted Aug 10, 2011·Updated Nov 14, 2023

In Brief

A Phase 2 clinical trial evaluating Smoking cessation counseling, Placebo, and 1 other intervention for Smoking Cessation. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This Investigator Initiated Research Award (IIR Award #WS981308) is a two-part pilot study that aims to examine acceptability and feasibility of varenicline use during an acute (72-hr) smoke-free hospitalization (Part 1) and 4-weeks post-hospitalization (Part 2).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 10, 2011
Enrollment StartAug 1, 2011
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 14.9 years ago

Interventions

Smoking cessation counselingbehavioral

Counseling sessions provided by a trained smoking counselor

Placebodrug

Sugar pill without any active medication

Vareniclinedrug

Varenicline (an approved medication for smoking cessation)